Stephan Grupp Laboratory
Researchers at the Center for Childhood Cancer Research have developed a unique mouse model system to develop new strategies that induce immune-mediated protection against ALL disease progression.
Researchers at the Center for Childhood Cancer Research (CCCR) are studying perturbations in leukemia cell signal transduction networks for therapeutic intervention in high risk subtypes of childhood leukemias.
Chimeric antigen receptor T-cell (CART) therapy has shown significant efficacy in treating leukemia. Researchers are now evaluating its use in pediatric neuroblastoma.
Researchers are developing and evaluating chimeric antigen receptor (CAR)-modified T-cells to treat children with acute lymphoblastic leukemia (ALL).
Clinical trials are underway at the Center for Childhood Cancer Research to evaluate the use of sirolimus as a treatment for refractory pediatric autoimmune diseases.
Researchers at the Center for Childhood Cancer Research have shown that early lineage T cell enrichment can help to improve and expand the use of engineered T cell immunotherapies.
Researchers are analyzing clinical samples and medical outcomes data from AML clinical trials to establish possible molecular links between specific AML germline or somatic mutations and disease progression and treatment responsiveness.
Researchers at the CCCR performed chart review for 12 different AEs for pediatric patients enrolled in U.S.-based COG Phase III clinical trials for pediatric acute myeloid leukemia (AML). Results from this analysis showed the current system of AE reporting on cooperative group oncology trials had modest sensitivity and a demonstrable false positive rate.
Research is underway to determine how to prevent cytokine release syndrome, a side effect of CART-19 therapy.
Researchers at the Center for Childhood Cancer Research are investigating new immunotherapies using chimeric antigen receptor (CAR)-modified T cells to treat children with relapsed and refractory AML.